Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.

Blood cancer discovery - 1 Jul 2026

Senapati Jayastu, Kantarjian Hagop M, Ayoub Edward, Quesada Andres E, Loghavi Sanam, Sasaki Koji, Kadia Tapan M, Daver Naval, DiNardo Courtney D, Jain Akhil, McCabe Mikaela, Haddad Fadi G, Brandt Mark, Tang Guilin, Alvarado Yesid, Farish Kayla, Abbas Hussein A, Garcia-Manero Guillermo, Ravandi Farhad, Andreeff Michael, Borthakur Gautam

Abstract excerpt

Fludarabine, cytarabine, and G-CSF-based therapy (FLAG) yields approximately 60% 5-year overall survival (OS) in core-binding factor (CBF) acute myeloid leukemia (AML), with potential added benefit with gemtuzumab ozogamicin (GO). Although measurable residual disease (MRD) status via optimal quantitative polymerase chain reaction (qPCR) response (OPR; qPCR <0.1% at the end of induction and <0.01% during/after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factors

Share to Cytarabine

Share to Genomics

Share to Granulocyte Colony-Stimulating Factor

Share to Leukemia, Myeloid, Acute

Share to Treatment Outcome

Share to Vidarabine

Source

Open in PubMed Open full text

Identifiers

PMID: 41979452
DOI: 10.1158/2643-3230.BCD-25-0477
PMCID: PMC13126934

Genes

ASXL1
DNMT3A
KIT
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.PMID 41979452Read ↗

KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.Semantic proximity Read ↗

KIT and FLT3-ITD Mutations Do Not Predict Outcomes in Pediatric Core-Binding Factor Acute Myeloid Leukemia: Findings from the C-HUANAN-AML-15 Multicenter Cohort StudySemantic proximity Read ↗

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”Semantic proximity Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

[Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].Semantic proximity Read ↗

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.Semantic proximity Read ↗

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Semantic proximity Read ↗

Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group studySemantic proximity Read ↗

KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.